Table II.
Immune monitoring and clinical responses of patients completing APC/Gal therapy
| Case No. | Baseline NKT (%) | NKT (day max)a | Baseline NK (%) | NK (day max)a | ELISPOT (day max)b | Clinical Response | Follow (y) | Outcome (last point) |
|---|---|---|---|---|---|---|---|---|
| 002 | 0.0077 | 2.2 (d7, d28) | 7.0 | 0.9 (d7) | 110.0 (d70) | RF | 7.0 | Alive |
| 043 | 0.00496 | 1.4 (d49) | 6.1 | 1.1 (d35) | 56.5 (d49) | RF | 3.0 | Alive |
| 009 | 0.03 | 0.1 (d42) | 3.6 | 3.2 (d70) | 42.3 (d49) | R | 2.0 | Dead |
| 018 | 0.0183 | 0.5 (d35) | 3.7 | 2.8 (d70) | 28.3 (d49) | RF | 5.0 | Alive |
| 014 | 0.00131 | 2.6 (d7) | 11.7 | 1.1 (d35) | 26.0 (d49) | R | 3.7 | Alive |
| 045 | 0.00316 | 2.1 (d70) | 1.9 | 1.6 (d7) | 17.1 (d49) | R | 2.9 | Alive |
| 035 | 0.00424 | 2.3 (d70) | 4.2 | 5.1 (d70) | 14 (d28) | R | 3.6 | Alive |
| 038 | 0.00314 | 2.2 (d7) | 12.0 | 1.8 (d28) | 12.0 (d35) | R | 3.3 | Alive |
| 004 | 0.00297 | 1.6 (d7) | 7.2 | 3.7 (d70) | 10.7 (d49) | R | 6.3 | Alive |
| 006 | 0.023 | 0.3 (d7) | 2.3 | 1.2 (d70) | 9.9 (d49) | RF | 5.8 | Alive |
| 030 | 0.00365 | 1.6 (d42) | 14.1 | 1.0 (d7) | 9.0 (d28, d70) | RF | 3.8 | Alive |
| 034 | 0.00697 | 6.6 (d42) | 5.3 | 1.8 (d35) | 14 (d28) | RF | 3.5 | Alive |
| 016 | 0.0071 | 1.7 (d7) | 5.9 | 1.2 (d35) | 8 (d49) | R | 5.1 | Alive |
| 024 | 0.000697 | 6.5 (d7) | 9.0 | 1.6 (d70) | 7.7 (d28) | RF | 4.6 | Alive |
| 047 | 0.019 | 0.4 (d35) | 3.6 | 1.3 (d70) | 7.4 (d49) | RF | 2.9 | Alive |
| 026 | 0.00654 | 0.7 (d28) | 5.7 | 1.9 (d35) | 6.4 (d49) | R | 3.5 | Dead |
| 054 | 0.00267 | 1.1 (d28) | 16.5 | 1.2 (d35) | 5.8 (d49) | R | 0.9 | Alive |
| 046 | 0.00753 | 2.1 (d49) | 9.4 | 0.9 (d70) | 5.6 (d49) | RF | 2.8 | Alive |
| 022 | 0.014 | 1.6 (d7) | 2.2 | 1.1 (d35) | 4.7 (d7) | RF | 4.8 | Alive |
| 040 | 0.016 | 1.9 (d70) | 15.5 | 0.8 (d70) | 3.3 (d35) | RF | 3.0 | Alive |
| 013 | 0.00334 | 1.5 (d70) | 7.4 | 1.2 (d35) | 3.1 (d49) | RF | 5.0 | Alive |
| 051 | 0.018 | 0.7 (d7) | 1.8 | 2.5 (d49) | 2.8 (d7) | R | 2.8 | Alive |
| 055 | 0.015 | 0.7 (d49) | 11.8 | 0.8 (d28) | 2.3 (d49) | RF | 2.0 | Alive |
| 049 | 0.16 | 1.4 (d7) | 6.4 | 1.9 (d35) | 1.5 (d28) | RF | 2.8 | Alive |
| 041 | 0.011 | 0.4 (d7) | 9.9 | 1.4 (d7) | 1.2 (d28) | R | 3.2 | Alive |
| 020 | 1.6 | 0.5 (d35) | 3.8 | 1.9 (d28) | 0.8 (d42) | R | 4.8 | Alive |
| 039 | 0.012 | 1.6 (d28) | 8.9 | 0.9 (d35) | 0.6 (d28, d35, d49) | RF | 3.0 | Alive |
The line in the table shows the boundary of 2.0 × the increase rate of ELISPOT (day max). d, day; max, maximum; R, recurrence progressive; RF, recurrence-free.
a
Maximal fold increase to baseline in NKT cell or NK cell number during treatment. The time point is depicted in parentheses.
b
ELISPOT maximal fold increase to baseline in IFN-γ–producing cell number. The time point is depicted in parentheses.